Kbio Labs KRX:038530KOSDAQ
케이바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Kbio Labs reported revenue of ₩12.2bn, down 41.1% year on year, and operating profit of ₩520m. Kbio Labs (케이바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Kbio Labs quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩12.2bn | -41.1% | ₩520m margin 4.2% | −₩42.3bn |
| Q1 2026 | ₩15.9bn | -22.7% | −₩808m margin −5.1% | ₩2.3bn |
| Q4 2025 derived | ₩28.4bn | +13.9% | ₩1.3bn margin 4.6% | −₩1.6bn |
| Q3 2025 | ₩17.6bn | +6.4% | −₩125m margin −0.7% | −₩137m |
| Q2 2025 | ₩20.8bn | +9.3% | ₩9m margin 0.0% | −₩3.3bn |
| Q1 2025 | ₩20.5bn | +28.0% | ₩341m margin 1.7% | ₩48m |
| Q4 2024 derived | ₩24.9bn | +270.4% | ₩1.4bn margin 5.8% | −₩15.3bn |
| Q3 2024 | ₩16.5bn | +154.5% | ₩56m margin 0.3% | ₩648m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kbio Labs top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.